source
- Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo B therapySpruce Biosciences reported progress toward filing its enzyme replacement therapy, tralesinidase alfa (TA-ERT), for Sanfilippo syndrome type B, an ultra-rare lysosomal disorder. The company said t…
- Texas lawmaker warns Chinese biotech firms gaining early-stage advantage over U.S. industryRep. Nathaniel Moran, a Republican from Texas and member of the House Select Committee on China, told Fierce that the United States is overlooking how Chinese biotech companies are outpacing Americ…